Global Retinoblastoma Treatment
Global Retinoblastoma Treatment

Retinoblastoma Treatment Comprehensive Study by Type (Alkylating Agents, Antimetabolites, Microtubule Inhibitors, Cytotoxic Antibiotics, Topoisomerase Inhibitors), Application (Intraocular Retinoblastoma, Extraocular Retinoblastoma), End-User (Hospitals, Cancer Institutes, Ambulatory Centers), Treatment Type (Surgery, Radiation therapy, Laser Therapy (Photocoagulation), Cryotherapy, Thermotherapy, Others) Players and Region - Global Market Outlook to 2026

Retinoblastoma Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 250 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Retinoblastoma Treatment Market Overview:
Retinoblastoma is a rare malignancy that affects the retina, most commonly in youngsters. When retinoblastoma returns after being treated and diagnosed, it is known as recurrent retinoblastoma. Retinoblastoma, both extraocular and intraocular, may have a chance of remission. Retinoblastoma is a cancer of the retina that can affect one or both eyes. At first, retinoblastoma has few, if any, symptoms. When light is shone into the eye, such as when flash photography is used, a pupil may seem white. It's possible that your eyes are staring in opposite directions. Chemotherapy, radiation, and laser therapy are all options for treatment. Increased remissions or recurrence of the disease, as well as increased awareness among healthcare professionals and patients, are driving the retinoblastoma therapy industry. The retinoblastoma treatment industry is changing dramatically as pharmaceutical and medical device companies seek to get into a larger untapped market in developing and underdeveloped economies. Companies are constantly investing in the research and development of better therapeutic solutions for retinoblastoma. Some of the players profiled in the study are Oxular Limited (United Kingdom), Baxter International Inc. (United States), Bristol-Myers Squibb Company (United States), Cadila Pharmaceuticals (India), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Merck & Co. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States) and Spectrum Pharmaceuticals, Inc (United States).

On the basis of geography, the market of Retinoblastoma Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Retinoblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Surgery will boost the Retinoblastoma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Remissions or Recurrence of the Disease
  • Increasing Incidents of Cancer

Influencing Trend
  • Increasing Awareness among Healthcare Professionals and Patient

Restraints
  • Side Effects of Retinoblastoma Surgery
  • High Cost of Treatment

Opportunities
  • Increased Investment in Healthcare Industry
  • High Diagnosis and Treatment Rate of Retinoblastoma

Challenges
  • Stringent Regulatory Factors


Key Market Developments:


October 2020 Oxular Limited a leading retinal therapeutics development company, has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company's proprietary drug in development for the treatment of retinoblastoma.

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Retinoblastoma Treatment market on the basis of product [Alkylating Agents, Antimetabolites, Microtubule Inhibitors, Cytotoxic Antibiotics and Topoisomerase Inhibitors] , application [Intraocular Retinoblastoma and Extraocular Retinoblastoma], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Retinoblastoma Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Retinoblastoma Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are CryoConcepts LP (United States) and Amerigen Pharms Ltd (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Retinoblastoma Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Alkylating Agents
  • Antimetabolites
  • Microtubule Inhibitors
  • Cytotoxic Antibiotics
  • Topoisomerase Inhibitors
By Application
  • Intraocular Retinoblastoma
  • Extraocular Retinoblastoma
By End-User
  • Hospitals
  • Cancer Institutes
  • Ambulatory Centers

By Treatment Type
  • Surgery
  • Radiation therapy
  • Laser Therapy (Photocoagulation)
  • Cryotherapy
  • Thermotherapy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Remissions or Recurrence of the Disease
      • 3.2.2. Increasing Incidents of Cancer
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness among Healthcare Professionals and Patient
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Retinoblastoma Treatment, by Type, Application, End-User, Treatment Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Retinoblastoma Treatment (Value)
      • 5.2.1. Global Retinoblastoma Treatment by: Type (Value)
        • 5.2.1.1. Alkylating Agents
        • 5.2.1.2. Antimetabolites
        • 5.2.1.3. Microtubule Inhibitors
        • 5.2.1.4. Cytotoxic Antibiotics
        • 5.2.1.5. Topoisomerase Inhibitors
      • 5.2.2. Global Retinoblastoma Treatment by: Application (Value)
        • 5.2.2.1. Intraocular Retinoblastoma
        • 5.2.2.2. Extraocular Retinoblastoma
      • 5.2.3. Global Retinoblastoma Treatment by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Institutes
        • 5.2.3.3. Ambulatory Centers
      • 5.2.4. Global Retinoblastoma Treatment by: Treatment Type (Value)
        • 5.2.4.1. Surgery
        • 5.2.4.2. Radiation therapy
        • 5.2.4.3. Laser Therapy (Photocoagulation)
        • 5.2.4.4. Cryotherapy
        • 5.2.4.5. Thermotherapy
        • 5.2.4.6. Others
      • 5.2.5. Global Retinoblastoma Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Retinoblastoma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Oxular Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Pharmaceuticals (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Spectrum Pharmaceuticals, Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Retinoblastoma Treatment Sale, by Type, Application, End-User, Treatment Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Retinoblastoma Treatment (Value)
      • 7.2.1. Global Retinoblastoma Treatment by: Type (Value)
        • 7.2.1.1. Alkylating Agents
        • 7.2.1.2. Antimetabolites
        • 7.2.1.3. Microtubule Inhibitors
        • 7.2.1.4. Cytotoxic Antibiotics
        • 7.2.1.5. Topoisomerase Inhibitors
      • 7.2.2. Global Retinoblastoma Treatment by: Application (Value)
        • 7.2.2.1. Intraocular Retinoblastoma
        • 7.2.2.2. Extraocular Retinoblastoma
      • 7.2.3. Global Retinoblastoma Treatment by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Institutes
        • 7.2.3.3. Ambulatory Centers
      • 7.2.4. Global Retinoblastoma Treatment by: Treatment Type (Value)
        • 7.2.4.1. Surgery
        • 7.2.4.2. Radiation therapy
        • 7.2.4.3. Laser Therapy (Photocoagulation)
        • 7.2.4.4. Cryotherapy
        • 7.2.4.5. Thermotherapy
        • 7.2.4.6. Others
      • 7.2.5. Global Retinoblastoma Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Retinoblastoma Treatment: by Type(USD Million)
  • Table 2. Retinoblastoma Treatment Alkylating Agents , by Region USD Million (2015-2020)
  • Table 3. Retinoblastoma Treatment Antimetabolites , by Region USD Million (2015-2020)
  • Table 4. Retinoblastoma Treatment Microtubule Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Retinoblastoma Treatment Cytotoxic Antibiotics , by Region USD Million (2015-2020)
  • Table 6. Retinoblastoma Treatment Topoisomerase Inhibitors , by Region USD Million (2015-2020)
  • Table 7. Retinoblastoma Treatment: by Application(USD Million)
  • Table 8. Retinoblastoma Treatment Intraocular Retinoblastoma , by Region USD Million (2015-2020)
  • Table 9. Retinoblastoma Treatment Extraocular Retinoblastoma , by Region USD Million (2015-2020)
  • Table 10. Retinoblastoma Treatment: by End-User(USD Million)
  • Table 11. Retinoblastoma Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 12. Retinoblastoma Treatment Cancer Institutes , by Region USD Million (2015-2020)
  • Table 13. Retinoblastoma Treatment Ambulatory Centers , by Region USD Million (2015-2020)
  • Table 14. Retinoblastoma Treatment: by Treatment Type(USD Million)
  • Table 15. Retinoblastoma Treatment Surgery , by Region USD Million (2015-2020)
  • Table 16. Retinoblastoma Treatment Radiation therapy , by Region USD Million (2015-2020)
  • Table 17. Retinoblastoma Treatment Laser Therapy (Photocoagulation) , by Region USD Million (2015-2020)
  • Table 18. Retinoblastoma Treatment Cryotherapy , by Region USD Million (2015-2020)
  • Table 19. Retinoblastoma Treatment Thermotherapy , by Region USD Million (2015-2020)
  • Table 20. Retinoblastoma Treatment Others , by Region USD Million (2015-2020)
  • Table 21. South America Retinoblastoma Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 23. South America Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 24. South America Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 25. South America Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 26. Brazil Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 27. Brazil Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 28. Brazil Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 29. Brazil Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 30. Argentina Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 31. Argentina Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 32. Argentina Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 33. Argentina Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 34. Rest of South America Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 37. Rest of South America Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 38. Asia Pacific Retinoblastoma Treatment, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 42. Asia Pacific Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 43. China Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 44. China Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 45. China Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 46. China Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 47. Japan Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 48. Japan Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 49. Japan Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 50. Japan Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 51. India Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 52. India Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 53. India Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 54. India Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 55. South Korea Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 56. South Korea Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 57. South Korea Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 58. South Korea Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 59. Taiwan Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 60. Taiwan Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 61. Taiwan Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 62. Taiwan Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 63. Australia Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 64. Australia Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 65. Australia Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 66. Australia Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 71. Europe Retinoblastoma Treatment, by Country USD Million (2015-2020)
  • Table 72. Europe Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 73. Europe Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 74. Europe Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 75. Europe Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 76. Germany Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 77. Germany Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 78. Germany Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 79. Germany Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 80. France Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 81. France Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 82. France Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 83. France Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 84. Italy Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 85. Italy Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 86. Italy Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 87. Italy Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 88. United Kingdom Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 90. United Kingdom Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 91. United Kingdom Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 92. Netherlands Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 93. Netherlands Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 94. Netherlands Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 95. Netherlands Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 96. Rest of Europe Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 98. Rest of Europe Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 99. Rest of Europe Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 100. MEA Retinoblastoma Treatment, by Country USD Million (2015-2020)
  • Table 101. MEA Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 102. MEA Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 103. MEA Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 104. MEA Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 105. Middle East Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 106. Middle East Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 107. Middle East Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 108. Middle East Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 109. Africa Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 110. Africa Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 111. Africa Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 112. Africa Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 113. North America Retinoblastoma Treatment, by Country USD Million (2015-2020)
  • Table 114. North America Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 115. North America Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 116. North America Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 117. North America Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 118. United States Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 119. United States Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 120. United States Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 121. United States Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 122. Canada Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 123. Canada Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 124. Canada Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 125. Canada Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 126. Mexico Retinoblastoma Treatment, by Type USD Million (2015-2020)
  • Table 127. Mexico Retinoblastoma Treatment, by Application USD Million (2015-2020)
  • Table 128. Mexico Retinoblastoma Treatment, by End-User USD Million (2015-2020)
  • Table 129. Mexico Retinoblastoma Treatment, by Treatment Type USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Retinoblastoma Treatment: by Type(USD Million)
  • Table 141. Retinoblastoma Treatment Alkylating Agents , by Region USD Million (2021-2026)
  • Table 142. Retinoblastoma Treatment Antimetabolites , by Region USD Million (2021-2026)
  • Table 143. Retinoblastoma Treatment Microtubule Inhibitors , by Region USD Million (2021-2026)
  • Table 144. Retinoblastoma Treatment Cytotoxic Antibiotics , by Region USD Million (2021-2026)
  • Table 145. Retinoblastoma Treatment Topoisomerase Inhibitors , by Region USD Million (2021-2026)
  • Table 146. Retinoblastoma Treatment: by Application(USD Million)
  • Table 147. Retinoblastoma Treatment Intraocular Retinoblastoma , by Region USD Million (2021-2026)
  • Table 148. Retinoblastoma Treatment Extraocular Retinoblastoma , by Region USD Million (2021-2026)
  • Table 149. Retinoblastoma Treatment: by End-User(USD Million)
  • Table 150. Retinoblastoma Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 151. Retinoblastoma Treatment Cancer Institutes , by Region USD Million (2021-2026)
  • Table 152. Retinoblastoma Treatment Ambulatory Centers , by Region USD Million (2021-2026)
  • Table 153. Retinoblastoma Treatment: by Treatment Type(USD Million)
  • Table 154. Retinoblastoma Treatment Surgery , by Region USD Million (2021-2026)
  • Table 155. Retinoblastoma Treatment Radiation therapy , by Region USD Million (2021-2026)
  • Table 156. Retinoblastoma Treatment Laser Therapy (Photocoagulation) , by Region USD Million (2021-2026)
  • Table 157. Retinoblastoma Treatment Cryotherapy , by Region USD Million (2021-2026)
  • Table 158. Retinoblastoma Treatment Thermotherapy , by Region USD Million (2021-2026)
  • Table 159. Retinoblastoma Treatment Others , by Region USD Million (2021-2026)
  • Table 160. South America Retinoblastoma Treatment, by Country USD Million (2021-2026)
  • Table 161. South America Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 162. South America Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 163. South America Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 164. South America Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 165. Brazil Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 166. Brazil Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 167. Brazil Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 168. Brazil Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 169. Argentina Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 170. Argentina Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 171. Argentina Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 172. Argentina Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 173. Rest of South America Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 174. Rest of South America Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 175. Rest of South America Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 176. Rest of South America Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 177. Asia Pacific Retinoblastoma Treatment, by Country USD Million (2021-2026)
  • Table 178. Asia Pacific Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 179. Asia Pacific Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 180. Asia Pacific Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 181. Asia Pacific Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 182. China Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 183. China Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 184. China Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 185. China Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 186. Japan Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 187. Japan Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 188. Japan Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 189. Japan Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 190. India Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 191. India Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 192. India Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 193. India Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 194. South Korea Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 195. South Korea Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 196. South Korea Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 197. South Korea Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 198. Taiwan Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 199. Taiwan Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 200. Taiwan Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 201. Taiwan Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 202. Australia Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 203. Australia Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 204. Australia Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 205. Australia Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 210. Europe Retinoblastoma Treatment, by Country USD Million (2021-2026)
  • Table 211. Europe Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 212. Europe Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 213. Europe Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 214. Europe Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 215. Germany Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 216. Germany Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 217. Germany Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 218. Germany Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 219. France Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 220. France Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 221. France Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 222. France Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 223. Italy Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 224. Italy Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 225. Italy Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 226. Italy Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 227. United Kingdom Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 228. United Kingdom Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 229. United Kingdom Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 230. United Kingdom Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 231. Netherlands Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 232. Netherlands Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 233. Netherlands Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 234. Netherlands Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 235. Rest of Europe Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 236. Rest of Europe Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 237. Rest of Europe Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 238. Rest of Europe Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 239. MEA Retinoblastoma Treatment, by Country USD Million (2021-2026)
  • Table 240. MEA Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 241. MEA Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 242. MEA Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 243. MEA Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 244. Middle East Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 245. Middle East Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 246. Middle East Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 247. Middle East Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 248. Africa Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 249. Africa Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 250. Africa Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 251. Africa Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 252. North America Retinoblastoma Treatment, by Country USD Million (2021-2026)
  • Table 253. North America Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 254. North America Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 255. North America Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 256. North America Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 257. United States Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 258. United States Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 259. United States Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 260. United States Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 261. Canada Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 262. Canada Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 263. Canada Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 264. Canada Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 265. Mexico Retinoblastoma Treatment, by Type USD Million (2021-2026)
  • Table 266. Mexico Retinoblastoma Treatment, by Application USD Million (2021-2026)
  • Table 267. Mexico Retinoblastoma Treatment, by End-User USD Million (2021-2026)
  • Table 268. Mexico Retinoblastoma Treatment, by Treatment Type USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Retinoblastoma Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Retinoblastoma Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Retinoblastoma Treatment: by End-User USD Million (2015-2020)
  • Figure 7. Global Retinoblastoma Treatment: by Treatment Type USD Million (2015-2020)
  • Figure 8. South America Retinoblastoma Treatment Share (%), by Country
  • Figure 9. Asia Pacific Retinoblastoma Treatment Share (%), by Country
  • Figure 10. Europe Retinoblastoma Treatment Share (%), by Country
  • Figure 11. MEA Retinoblastoma Treatment Share (%), by Country
  • Figure 12. North America Retinoblastoma Treatment Share (%), by Country
  • Figure 13. Global Retinoblastoma Treatment share by Players 2020 (%)
  • Figure 14. Global Retinoblastoma Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Retinoblastoma Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Oxular Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Oxular Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Baxter International Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 23. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 24. Cadila Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 29. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Spectrum Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Spectrum Pharmaceuticals, Inc (United States) Revenue: by Geography 2020
  • Figure 37. Global Retinoblastoma Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Retinoblastoma Treatment: by Application USD Million (2021-2026)
  • Figure 39. Global Retinoblastoma Treatment: by End-User USD Million (2021-2026)
  • Figure 40. Global Retinoblastoma Treatment: by Treatment Type USD Million (2021-2026)
  • Figure 41. South America Retinoblastoma Treatment Share (%), by Country
  • Figure 42. Asia Pacific Retinoblastoma Treatment Share (%), by Country
  • Figure 43. Europe Retinoblastoma Treatment Share (%), by Country
  • Figure 44. MEA Retinoblastoma Treatment Share (%), by Country
  • Figure 45. North America Retinoblastoma Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Oxular Limited (United Kingdom)
  • Baxter International Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • Cadila Pharmaceuticals (India)
  • GlaxoSmithKline plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Merck & Co. (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Spectrum Pharmaceuticals, Inc (United States)
Additional players considered in the study are as follows:
CryoConcepts LP (United States) , Amerigen Pharms Ltd (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation